Recently, CFTR triple modulator therapy (elexacaftor/tezacaftor/ivacaftor), which restores CFTR-dependent anion and fluid secretion in CF airway epithelial cells, has been approved for pwCF carrying at least one copy of the most common F508del class II trafficking mutation [4,5]. This evidence concerns the gene CFTR and cystic fibrosis.